Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 22, 2026--

Summary of reporting by rutlandherald 1 min read Markdown

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/vistagen-receives-fda-study-may-proceed-letter-under-its-refisolone-ind-application-enabling-further-phase/article_17520fd3-203b-5e31-8c49-0731ba5de28d.html

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.